|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.94 CAD | -4.45% |
|
-1.98% | +25.06% |
| Apr. 08 | HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA | CI |
| Mar. 14 | Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024 |
HLS Therapeutics Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was USD 60.01 million compared to USD 56.11 million a year ago. Net loss was USD 13.12 million compared to USD 15.33 million a year ago.
Basic loss per share from continuing operations was USD 0.41 compared to USD 0.48 a year ago. Diluted loss per share from continuing operations was USD 0.41 compared to USD 0.48 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +25.06% | 114M | |
| +12.89% | 68.68B | |
| +6.18% | 26.03B | |
| -4.45% | 7.86B | |
| +3.53% | 7.94B | |
| -28.85% | 7.13B | |
| +1.10% | 4.59B | |
| +19.12% | 4.39B | |
| 0.00% | 4.06B | |
| -3.30% | 3.85B |
HLS THERAPEUTICS INC. 
